| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Survivors | 21 | 2025 | 247 | 5.180 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 17 | 2025 | 809 | 3.050 |
Why?
|
| Leukemia, Myeloid, Acute | 14 | 2024 | 569 | 2.580 |
Why?
|
| Neoplasms, Second Primary | 6 | 2025 | 164 | 2.450 |
Why?
|
| Neoplasms | 18 | 2025 | 3027 | 2.100 |
Why?
|
| Thyroid Neoplasms | 4 | 2021 | 255 | 1.950 |
Why?
|
| Telomere | 4 | 2016 | 230 | 1.440 |
Why?
|
| Hematologic Neoplasms | 3 | 2024 | 295 | 1.220 |
Why?
|
| Hodgkin Disease | 4 | 2024 | 298 | 1.200 |
Why?
|
| Telomere Shortening | 2 | 2021 | 36 | 1.140 |
Why?
|
| Child | 54 | 2025 | 25742 | 1.120 |
Why?
|
| Telomerase | 3 | 2020 | 179 | 1.100 |
Why?
|
| Survivorship | 3 | 2024 | 44 | 1.080 |
Why?
|
| Mycoses | 2 | 2021 | 121 | 0.990 |
Why?
|
| Health Equity | 2 | 2024 | 67 | 0.950 |
Why?
|
| Neutropenia | 5 | 2023 | 201 | 0.920 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 1353 | 0.890 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2022 | 1189 | 0.860 |
Why?
|
| Telomere-Binding Proteins | 3 | 2020 | 46 | 0.860 |
Why?
|
| Neurotoxicity Syndromes | 4 | 2025 | 63 | 0.830 |
Why?
|
| Dyskeratosis Congenita | 2 | 2013 | 19 | 0.820 |
Why?
|
| Adolescent | 35 | 2025 | 20536 | 0.790 |
Why?
|
| Telomere Homeostasis | 2 | 2020 | 47 | 0.760 |
Why?
|
| Patient Preference | 1 | 2023 | 135 | 0.760 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 102 | 0.740 |
Why?
|
| Radiotherapy | 3 | 2021 | 148 | 0.740 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 3475 | 0.720 |
Why?
|
| Frailty | 2 | 2021 | 131 | 0.720 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2022 | 117 | 0.700 |
Why?
|
| Health Status Disparities | 1 | 2024 | 246 | 0.700 |
Why?
|
| Hyperbilirubinemia | 2 | 2022 | 42 | 0.690 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 1850 | 0.670 |
Why?
|
| Methotrexate | 5 | 2025 | 355 | 0.660 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 195 | 0.660 |
Why?
|
| Humans | 70 | 2025 | 133943 | 0.660 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2025 | 197 | 0.660 |
Why?
|
| Antifungal Agents | 3 | 2024 | 309 | 0.630 |
Why?
|
| Internet | 2 | 2022 | 402 | 0.620 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 282 | 0.620 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 107 | 0.620 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2020 | 129 | 0.610 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 6 | 0.610 |
Why?
|
| Caregivers | 1 | 2023 | 583 | 0.580 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 75 | 0.570 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 129 | 0.570 |
Why?
|
| Long Term Adverse Effects | 1 | 2017 | 12 | 0.570 |
Why?
|
| Young Adult | 18 | 2025 | 9890 | 0.560 |
Why?
|
| Down Syndrome | 1 | 2020 | 231 | 0.550 |
Why?
|
| Siblings | 3 | 2019 | 198 | 0.550 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 59 | 0.540 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 175 | 0.540 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2020 | 2940 | 0.540 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 332 | 0.520 |
Why?
|
| Infertility | 1 | 2017 | 82 | 0.520 |
Why?
|
| Leukemia, Myeloid | 1 | 2016 | 82 | 0.520 |
Why?
|
| Genetic Variation | 2 | 2020 | 1621 | 0.500 |
Why?
|
| Cognition Disorders | 1 | 2020 | 579 | 0.500 |
Why?
|
| Survivors | 5 | 2024 | 360 | 0.480 |
Why?
|
| Prognosis | 9 | 2024 | 5081 | 0.470 |
Why?
|
| Female | 38 | 2025 | 71684 | 0.470 |
Why?
|
| Child, Preschool | 19 | 2025 | 14802 | 0.460 |
Why?
|
| Risk Factors | 16 | 2025 | 11101 | 0.450 |
Why?
|
| Male | 34 | 2025 | 65904 | 0.440 |
Why?
|
| Neutrophils | 1 | 2016 | 401 | 0.440 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1720 | 0.410 |
Why?
|
| Minisatellite Repeats | 1 | 2013 | 43 | 0.410 |
Why?
|
| Anemia, Aplastic | 1 | 2013 | 62 | 0.400 |
Why?
|
| Papillomavirus Vaccines | 2 | 2025 | 106 | 0.390 |
Why?
|
| Proportional Hazards Models | 5 | 2023 | 1484 | 0.390 |
Why?
|
| Steroids | 1 | 2013 | 210 | 0.390 |
Why?
|
| Obesity | 3 | 2018 | 2416 | 0.360 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 34 | 0.350 |
Why?
|
| Fetal Growth Retardation | 1 | 2013 | 248 | 0.350 |
Why?
|
| Hematology | 1 | 2011 | 41 | 0.340 |
Why?
|
| Incidence | 5 | 2024 | 3402 | 0.340 |
Why?
|
| Cardiomyopathies | 2 | 2025 | 514 | 0.340 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 920 | 0.330 |
Why?
|
| Microcephaly | 1 | 2013 | 347 | 0.330 |
Why?
|
| Thrombocytopenia, Neonatal Alloimmune | 1 | 2009 | 2 | 0.320 |
Why?
|
| Adult | 17 | 2025 | 31950 | 0.320 |
Why?
|
| Wolman Disease | 1 | 2009 | 7 | 0.310 |
Why?
|
| Sterol Esterase | 1 | 2009 | 20 | 0.310 |
Why?
|
| Isoantibodies | 1 | 2009 | 72 | 0.310 |
Why?
|
| Papillomavirus Infections | 2 | 2025 | 398 | 0.310 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2009 | 85 | 0.310 |
Why?
|
| Cellular Senescence | 1 | 2010 | 201 | 0.310 |
Why?
|
| Case-Control Studies | 4 | 2021 | 3639 | 0.300 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 5511 | 0.300 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 2087 | 0.300 |
Why?
|
| Retrospective Studies | 16 | 2025 | 17488 | 0.300 |
Why?
|
| Anthracyclines | 3 | 2025 | 44 | 0.290 |
Why?
|
| HLA Antigens | 1 | 2009 | 253 | 0.290 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 679 | 0.260 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1494 | 0.260 |
Why?
|
| Societies, Medical | 1 | 2011 | 777 | 0.250 |
Why?
|
| Texas | 4 | 2023 | 3689 | 0.250 |
Why?
|
| Electronics | 2 | 2023 | 47 | 0.250 |
Why?
|
| Lymphocyte Count | 3 | 2022 | 125 | 0.250 |
Why?
|
| Intellectual Disability | 1 | 2013 | 1076 | 0.240 |
Why?
|
| Connectin | 1 | 2025 | 28 | 0.240 |
Why?
|
| Infant | 11 | 2024 | 13163 | 0.230 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 37 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 1335 | 0.230 |
Why?
|
| Candida tropicalis | 1 | 2024 | 17 | 0.230 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2025 | 168 | 0.220 |
Why?
|
| Candidiasis, Invasive | 1 | 2024 | 23 | 0.220 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 3990 | 0.220 |
Why?
|
| Medical Oncology | 1 | 2025 | 244 | 0.210 |
Why?
|
| Body Fluids | 1 | 2023 | 49 | 0.200 |
Why?
|
| Asparaginase | 1 | 2022 | 48 | 0.190 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 57 | 0.190 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 50 | 0.190 |
Why?
|
| Central Venous Catheters | 1 | 2022 | 43 | 0.190 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2025 | 619 | 0.180 |
Why?
|
| Pancreatitis | 1 | 2022 | 144 | 0.180 |
Why?
|
| Catheter-Related Infections | 1 | 2022 | 104 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2021 | 5182 | 0.170 |
Why?
|
| Aftercare | 2 | 2022 | 155 | 0.170 |
Why?
|
| Catheterization, Central Venous | 1 | 2022 | 135 | 0.170 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 33 | 0.170 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 29 | 0.170 |
Why?
|
| Middle Aged | 6 | 2023 | 29409 | 0.170 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 971 | 0.170 |
Why?
|
| Hypersensitivity | 1 | 2022 | 197 | 0.160 |
Why?
|
| Poverty | 1 | 2023 | 435 | 0.160 |
Why?
|
| Echocardiography, Doppler | 1 | 2020 | 173 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 135 | 0.160 |
Why?
|
| Parents | 2 | 2023 | 1060 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 216 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 178 | 0.160 |
Why?
|
| Genome-Wide Association Study | 2 | 2024 | 1871 | 0.160 |
Why?
|
| Infant, Newborn | 6 | 2024 | 8591 | 0.150 |
Why?
|
| Fatal Outcome | 2 | 2011 | 376 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2022 | 325 | 0.150 |
Why?
|
| Introns | 1 | 2020 | 313 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2020 | 165 | 0.150 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 412 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2025 | 794 | 0.150 |
Why?
|
| Aging, Premature | 1 | 2018 | 30 | 0.150 |
Why?
|
| Remission Induction | 2 | 2016 | 308 | 0.150 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 12 | 0.150 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1814 | 0.150 |
Why?
|
| Gene Frequency | 1 | 2020 | 778 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 187 | 0.140 |
Why?
|
| Cerebellar Neoplasms | 1 | 2022 | 461 | 0.140 |
Why?
|
| Heart Atria | 1 | 2020 | 333 | 0.140 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 48 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 254 | 0.140 |
Why?
|
| Stroke Volume | 1 | 2020 | 530 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 307 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 611 | 0.140 |
Why?
|
| Sepsis | 1 | 2022 | 517 | 0.140 |
Why?
|
| Medulloblastoma | 1 | 2022 | 570 | 0.140 |
Why?
|
| Leukocytes | 1 | 2018 | 225 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 381 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 2763 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2018 | 133 | 0.130 |
Why?
|
| Bone Marrow | 1 | 2018 | 335 | 0.130 |
Why?
|
| Longevity | 1 | 2018 | 158 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2020 | 401 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 544 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 844 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 1484 | 0.130 |
Why?
|
| Parent-Child Relations | 1 | 2017 | 253 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2020 | 1254 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 696 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 626 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2020 | 522 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2025 | 3699 | 0.120 |
Why?
|
| Alleles | 1 | 2020 | 1705 | 0.120 |
Why?
|
| Quality of Life | 2 | 2024 | 2143 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2018 | 395 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 796 | 0.120 |
Why?
|
| Biopsy | 1 | 2018 | 1304 | 0.110 |
Why?
|
| Philadelphia Chromosome | 1 | 2014 | 43 | 0.110 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 42 | 0.110 |
Why?
|
| Echocardiography | 1 | 2020 | 1124 | 0.110 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 54 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 934 | 0.110 |
Why?
|
| Algorithms | 1 | 2021 | 1736 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1139 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1407 | 0.110 |
Why?
|
| Inpatients | 1 | 2017 | 534 | 0.100 |
Why?
|
| Acute Disease | 1 | 2016 | 1191 | 0.100 |
Why?
|
| Mutation | 2 | 2020 | 6297 | 0.100 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 140 | 0.100 |
Why?
|
| Pedigree | 2 | 2014 | 1694 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2013 | 330 | 0.100 |
Why?
|
| Epilepsy | 1 | 2020 | 892 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 148 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 362 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 368 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 444 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 680 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2018 | 1143 | 0.090 |
Why?
|
| Homozygote | 1 | 2013 | 560 | 0.090 |
Why?
|
| Anxiety | 1 | 2017 | 993 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1489 | 0.080 |
Why?
|
| Glioma | 1 | 2014 | 537 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1596 | 0.080 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2009 | 37 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 2296 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1153 | 0.070 |
Why?
|
| Liver Failure | 1 | 2009 | 91 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2010 | 482 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2025 | 6664 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 508 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 300 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 1302 | 0.060 |
Why?
|
| Neuroblastoma | 1 | 2010 | 539 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 1409 | 0.060 |
Why?
|
| Drug Resistance, Fungal | 1 | 2024 | 30 | 0.060 |
Why?
|
| Selection Bias | 1 | 2024 | 22 | 0.060 |
Why?
|
| Pediatrics | 2 | 2025 | 1217 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 196 | 0.050 |
Why?
|
| Apoptosis | 1 | 2010 | 1930 | 0.050 |
Why?
|
| Risk | 2 | 2018 | 832 | 0.050 |
Why?
|
| Recurrence | 2 | 2020 | 1471 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 107 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 41 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 247 | 0.050 |
Why?
|
| Machine Learning | 1 | 2025 | 331 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2024 | 828 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2022 | 189 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2021 | 93 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2022 | 251 | 0.040 |
Why?
|
| Creatinine | 1 | 2023 | 429 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 252 | 0.040 |
Why?
|
| Biomarkers | 1 | 2010 | 3426 | 0.040 |
Why?
|
| Age Factors | 2 | 2020 | 2979 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2022 | 300 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 4548 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 983 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2020 | 38 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2014 | 836 | 0.040 |
Why?
|
| Systole | 1 | 2020 | 206 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2021 | 416 | 0.040 |
Why?
|
| Vaccination | 1 | 2025 | 1011 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 312 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 384 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 789 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 479 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1088 | 0.040 |
Why?
|
| Family | 1 | 2021 | 588 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 456 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 224 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 630 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2020 | 13013 | 0.040 |
Why?
|
| Bleomycin | 1 | 2018 | 153 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 168 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 1206 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 231 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 773 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 187 | 0.030 |
Why?
|
| Pregnancy | 1 | 2009 | 7522 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 1417 | 0.030 |
Why?
|
| Registries | 1 | 2023 | 1565 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 573 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 885 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2022 | 790 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 25 | 0.030 |
Why?
|
| Hospitalization | 1 | 2023 | 1890 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 718 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 3056 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 2655 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 1713 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 905 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 3740 | 0.020 |
Why?
|
| Aged | 2 | 2023 | 21746 | 0.020 |
Why?
|
| Lung | 1 | 2018 | 1557 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6590 | 0.020 |
Why?
|
| Gangliosides | 1 | 2010 | 72 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1067 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 257 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2196 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 296 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3077 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 1102 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 247 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 724 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1134 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1326 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 486 | 0.020 |
Why?
|
| United States | 1 | 2020 | 11687 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2902 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 2539 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 4899 | 0.010 |
Why?
|